New pill aims to keep narcolepsy patients awake and steady

NCT ID NCT07540897

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improvements in staying awake and overall symptom severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ALKS 2680 (alixorexton) tablets
What this could lead to
If successful, this could provide a new daily medication to better control excessive daytime sleepiness and sudden muscle weakness in people with narcolepsy type 1.
What could go wrong
This is a phase 3 trial, but it is still experimental. The drug may not work better than a placebo, and side effects are possible. It is not a cure, and long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence narcolepsy-cataplexy syndrome sleep-wake disorder Sleepiness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alkermes Investigational Site

    RECRUITING

    Miami, Florida, 33176, United States

  • Alkermes Investigational Site

    RECRUITING

    Winter Park, Florida, 32789, United States

  • Alkermes Investigational Site

    RECRUITING

    Atlanta, Georgia, 30328, United States

  • Alkermes Investigational Site

    RECRUITING

    Macon, Georgia, 31210, United States

  • Alkermes Investigational Site

    RECRUITING

    Lansing, Michigan, 48911, United States

  • Alkermes Investigational Site

    RECRUITING

    St Louis, Missouri, 63123, United States

  • Alkermes Investigational Site

    RECRUITING

    Charlotte, North Carolina, 28210, United States

  • Alkermes Investigational Site

    RECRUITING

    Cincinnati, Ohio, 45245, United States

  • Alkermes Investigational Site

    RECRUITING

    Colombia, South Carolina, 29201, United States

  • Alkermes Investigational Site

    RECRUITING

    Dallas, Texas, 75251, United States

  • Alkermes Investigational Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Alkermes Investigational Site

    RECRUITING

    Sugar Land, Texas, 77478, United States

  • Alkermes Investigational Site

    RECRUITING

    Markham, Ontario, L3R 1A3, Canada

  • Alkermes Investigational Site

    RECRUITING

    Toronto, Ontario, M5S 3A3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.